Human coagulation factor VIII

Human Coagulation Factor VIII, also known as Antihemophilic Factor or Factor VIII:C, is a medically prescribed protein that is used to treat and prevent bleeding episodes in individuals with Hemophilia A, a genetic disorder that affects the blood’s ability to clot. Hemophilia A is caused by a deficiency or dysfunction of Factor VIII, a vital component in the clotting process.
Factor VIII works by assisting in the formation of a blood clot, which helps to stop bleeding and promote healing. When a person with Hemophilia A receives Factor VIII replacement therapy, it replenishes the missing or defective protein, thereby restoring the blood’s ability to clot effectively.
Factor VIII is available in both liquid and powder forms and can be administered through intravenous injection. The treatment is typically prescribed on an as-needed basis to manage bleeding episodes, as well as for routine prophylaxis to prevent bleeding in individuals with severe Hemophilia A.
Factor VIII is a blood-derived product, and therefore carries a small risk of transmitting infectious agents, such as viruses. However, rigorous screening and manufacturing processes have significantly reduced these risks to a minimal level.